Texas Gastro Clinic
Welcome,         Profile    Billing    Logout  
 6 Trials 
17 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
McKay, Heather A
NCT04469686 / 2019-003596-19: Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories

Completed
3
200
US
Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator, Twice Daily - Active, Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator, Once Daily - Active, Twice daily placebo suppository administered with Sephure applicator, Twice Daily - Placebo
Cristcot LLC, Cristcot HCA LLC
Ulcerative Proctitis
07/24
09/24
NCT06434298: Provincial Scale-up of Choose to Move (CTM) Phase 4

Enrolling by invitation
N/A
5720
Canada
Choose to Move
University of British Columbia, British Columbia Ministry of Health
Aging, Physical Inactivity, Mobility Limitation, Loneliness, Social Isolation
08/26
08/27
CTM-NS, NCT04592614: Choose to Move - Next Steps: Can 'Booster Sessions' Sustain Health Benefits of an Effective, Scaled-up, Health Promotion Program?

Active, not recruiting
N/A
424
Canada
Choose to Move - Next Steps
University of British Columbia, Canadian Institutes of Health Research (CIHR), Active Aging Society
Aging, Mobility Limitation, Sedentary Behavior, Loneliness, Social Isolation
02/24
02/24
NCT06446414: Evaluating Implementation and Impact of Provincial Scale-up of the Adapted Choose to Move (CTM) Program

Enrolling by invitation
N/A
300
Canada
Choose to Move
University of British Columbia, Public Health Agency of Canada (PHAC)
Aging, Mobility Limitation, Physical Inactivity, Loneliness, Social Isolation
04/27
04/27
CTM, NCT06252259: Evaluating Implementation and Impact of the Adapted Choose to Move () Program

Enrolling by invitation
N/A
336
Canada
Choose to Move
University of British Columbia, Canadian Institutes of Health Research (CIHR), Active Aging Society
Aging, Mobility Limitation, Physical Inactivity, Sedentary Behavior, Loneliness, Social Isolation
03/27
03/27
ALTUS, NCT05064553: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk

Recruiting
N/A
2500
US
Study CT/MRI Imaging, Standard of Care CT/MRI Imaging, Oncoguard™ Liver Test
Exact Sciences Corporation
Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer
01/25
04/26
CTM, NCT05678985: Evaluating Impact and Implementation of Choose to Move (Phase 4)

Active, not recruiting
N/A
1000
Canada
Choose to Move
University of British Columbia, Canadian Institutes of Health Research (CIHR), Active Aging Society
Aging, Mobility Limitation, Sedentary Behaviour, Loneliness, Social Isolation, Social Connectedness
01/25
01/25
Roberts, Lewis
NCT02419079: DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection

Not yet recruiting
1/2
116
US
DNA Plasmid Encoding Interleukin-12 INO-9012, INO-9012, Electroporation-Mediated Plasmid DNA Vaccine Therapy, HCV DNA Vaccine INO-8000, Laboratory Biomarker Analysis, Placebo, placebo, placebo therapy, PLCB, sham therapy, Quality-of-Life Assessment, Quality of Life Assessment
National Cancer Institute (NCI)
Chronic Hepatitis, Hepatitis C Infection
10/17
 
NCT03942328: Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Recruiting
1/2
54
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Zirabev, External Beam Radiation Therapy, Definitive Radiation Therapy, EBRT, External Beam Radiation, External Beam Radiotherapy, External Beam Radiotherapy (conventional), External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Radiation, External Beam, Teleradiotherapy, Teletherapy, Teletherapy Radiation, Pheresis, Apheresed, Apheresis, Blood Component Removal, Collection, Apheresis/Leukapheresis, Hemapheresis, Pneumococcal 13-valent Conjugate Vaccine, PCV 13, PCV13 Vaccine, Prevnar 13, Therapeutic Autologous Dendritic Cells
Mayo Clinic, National Cancer Institute (NCI)
Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Hepatocellular Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
08/27
02/28
NCT02822079: DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection

Recruiting
1
32
US
DNA Plasmid Encoding Interleukin-12 INO-9012, INO-9012, Electroporation-Mediated Plasmid DNA Vaccine Therapy, HCV DNA Vaccine INO-8000, INO-8000, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment
Mayo Clinic, Inovio Pharmaceuticals, National Cancer Institute (NCI)
Chronic Hepatitis, Hepatitis C Infection
03/20
 
NCT03878550: Case-Control Study of the Glycotest™ HCC Panel vs AFP for the Detection of Early-stage Hepatocellular Carcinoma

Active, not recruiting
N/A
766
US, RoW
Glycotest, Inc.
Carcinoma, Hepatocellular, Cirrhosis, Liver
08/23
12/24
ALTUS, NCT05064553: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk

Recruiting
N/A
2500
US
Study CT/MRI Imaging, Standard of Care CT/MRI Imaging, Oncoguard™ Liver Test
Exact Sciences Corporation
Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer
01/25
04/26
Gorospe, Emmanuel
NCT05832151: A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

Recruiting
2
288
US
CIN-102 Dose 15mg or 10mg, Placebo
CinDome Pharma, Inc.
Diabetic Gastroparesis
09/25
09/25
HORIZON, NCT05583344 / 2022-002538-14: Phase 2b Study of GSK4532990 in Adults With NASH

Active, not recruiting
2
271
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
12/25
03/26
ALTUS, NCT05064553: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk

Recruiting
N/A
2500
US
Study CT/MRI Imaging, Standard of Care CT/MRI Imaging, Oncoguard™ Liver Test
Exact Sciences Corporation
Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer
01/25
04/26
Leon, Marissa Diaz de
ALTUS, NCT05064553: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk

Recruiting
N/A
2500
US
Study CT/MRI Imaging, Standard of Care CT/MRI Imaging, Oncoguard™ Liver Test
Exact Sciences Corporation
Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer
01/25
04/26
Moy, Si-Yeun
ALTUS, NCT05064553: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk

Recruiting
N/A
2500
US
Study CT/MRI Imaging, Standard of Care CT/MRI Imaging, Oncoguard™ Liver Test
Exact Sciences Corporation
Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer
01/25
04/26

Download Options